{"url_path":"/sec/jbio/8-k/2026-06-26/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-283906-index.html","accession_number":"0001193125-26-283906","cik":"0001798749","ticker":"JBIO","issuer_name":"Jade Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-283906-index.html","primary_entity_key":"0001798749","primary_entity_name":"Jade Biosciences, Inc."},"word_count":124,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure\n\nOn June 26, 2026, the Company issued a press release announcing Dr. Eisner’s election to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}